作者: S. M. Watt , S. P. Forde
DOI: 10.1111/J.1423-0410.2007.00995.X
关键词:
摘要: Recent clinical trials have used CXCR4 antagonists for the rapid mobilization of CD34(+) haemopoietic stem/progenitor cells (HSC/HPC) from bone marrow to blood in patients refractory granulocyte-colony-stimulating factor (G-CSF). These not only mobilize non-cycling with a higher proportion repopulating cells, but also enhance cell when combination G-CSF. Here, we review importance and its ligand CXCL12 haemopoiesis, potential roles HSC transplant setting.